Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin Combined With Lisaftoclax in CD30-positive CTCL
NCT07717580Phase 2Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Jul 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lisaftoclax in cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) and primary cutaneous anaplastic large cell lymphoma (PCALCL) (2 arms), sponsored by Peking University First Hospital. Primary endpoint: Objective Response Rate at 48 weeks. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
lisaftoclax
03
Conditions
cutaneous T-cell lymphoma (CTCL)mycosis fungoides (MF)primary cutaneous anaplastic large cell lymphoma (PCALCL)
Beyond the preview
Go deeper on NCT07717580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07717580.